{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Period+B&page=5",
    "query": {
      "intervention": "Period B",
      "page": 5
    },
    "page_size": 10
  },
  "pagination": {
    "page": 5,
    "page_size": 10,
    "total_count": 1570,
    "total_pages": 157,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Period+B&page=6&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Period+B&page=4&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-27T03:06:52.841Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04235270",
      "title": "A Study of Macitentan and Tadalafil as a Fixed Dose Combination and the Free Combination in Healthy Adult Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "FDC of Macitentan and Tadalafil",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Macitentan",
          "type": "DRUG"
        },
        {
          "name": "Tadalafil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT",
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 62,
      "start_date": "2020-01-17",
      "completion_date": "2020-07-17",
      "has_results": false,
      "last_update_posted_date": "2025-03-30",
      "last_synced_at": "2026-10-27T03:06:52.841Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04235270"
    },
    {
      "nct_id": "NCT01776437",
      "title": "Study of BMN 673, a PARP Inhibitor, in Healthy Adult Male Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Human Volunteers"
      ],
      "interventions": [
        {
          "name": "BMN 673",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "MALE",
        "summary": "18 Years to 55 Years · Male only"
      },
      "enrollment_count": 18,
      "start_date": "2013-02",
      "completion_date": "2013-07",
      "has_results": false,
      "last_update_posted_date": "2017-07-28",
      "last_synced_at": "2026-10-27T03:06:52.841Z",
      "location_count": 1,
      "location_summary": "Evansville, Indiana",
      "locations": [
        {
          "city": "Evansville",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01776437"
    },
    {
      "nct_id": "NCT02933879",
      "title": "Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Multi-Site Phase 2b Clinical Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Onychomycosis"
      ],
      "interventions": [
        {
          "name": "NVXT topical",
          "type": "DRUG"
        },
        {
          "name": "Placebo (Vehicle) Topical",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sun Pharmaceutical Industries, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 184,
      "start_date": "2016-03-21",
      "completion_date": "2018-06-21",
      "has_results": true,
      "last_update_posted_date": "2018-12-20",
      "last_synced_at": "2026-10-27T03:06:52.841Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02933879"
    },
    {
      "nct_id": "NCT03059303",
      "title": "Study to Assess the Relative Bioavailability of Fixed-Dose Combination (FDC) Tablet (Simeprevir, Odalasvir and AL-335) Compared With Single Agents Administered Together, and to Assess the Effect of Multiple-Dose Lansoprazole or Omeprazole on Single-Dose Pharmacokinetics of SMV, ODV, and AL-335 (FDC)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Simeprevir 75 mg",
          "type": "DRUG"
        },
        {
          "name": "Odalasvir 25 mg",
          "type": "DRUG"
        },
        {
          "name": "Odalasvir 12.5 mg",
          "type": "DRUG"
        },
        {
          "name": "Odalasvir 75 mg",
          "type": "DRUG"
        },
        {
          "name": "AL-335 800 mg",
          "type": "DRUG"
        },
        {
          "name": "Lansoprazole 30 mg",
          "type": "DRUG"
        },
        {
          "name": "Omeprazole 20 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 72,
      "start_date": "2017-02-20",
      "completion_date": "2017-04-24",
      "has_results": false,
      "last_update_posted_date": "2017-12-22",
      "last_synced_at": "2026-10-27T03:06:52.841Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03059303"
    },
    {
      "nct_id": "NCT01604031",
      "title": "Treatment of B-CLL With Autologous IL2 and CD40 Ligand-Expressing Tumor Cells + Lenalidomide",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "B-cell Chronic Lymphocytic Leukemia"
      ],
      "interventions": [
        {
          "name": "B-CLL Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 2,
      "start_date": "2013-02",
      "completion_date": "2015-04",
      "has_results": false,
      "last_update_posted_date": "2016-02-08",
      "last_synced_at": "2026-10-27T03:06:52.841Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01604031"
    },
    {
      "nct_id": "NCT01332513",
      "title": "An Open Label, Randomised, Repeat Dose Study to Assess the Pharmacokinetic Performance of Five Ezogabine/Retigabine Modified Release (MR) Formulations at Steady State Compared to the Immediate Release (IR) Formulation.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Epilepsy"
      ],
      "interventions": [
        {
          "name": "Investigational Medicinal Product (MR1)",
          "type": "DRUG"
        },
        {
          "name": "Investigational Medicinal Product (MR2)",
          "type": "DRUG"
        },
        {
          "name": "Investigational Medicinal Product (MR3)",
          "type": "DRUG"
        },
        {
          "name": "Investigational Medicinal Product (MR4)",
          "type": "DRUG"
        },
        {
          "name": "Investigational Medicinal Product (MR5)",
          "type": "DRUG"
        },
        {
          "name": "Investigational Medicinal Product (IR)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 36,
      "start_date": "2011-02-10",
      "completion_date": "2011-05-23",
      "has_results": false,
      "last_update_posted_date": "2018-06-19",
      "last_synced_at": "2026-10-27T03:06:52.841Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01332513"
    },
    {
      "nct_id": "NCT03708224",
      "title": "Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cancer",
        "Carcinoma",
        "Squamous Cell Carcinoma",
        "Head and Neck Cancer"
      ],
      "interventions": [
        {
          "name": "Atezolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Tocilizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Tiragolumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Alain Algazi",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 55,
      "start_date": "2019-03-08",
      "completion_date": "2027-07-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-11",
      "last_synced_at": "2026-10-27T03:06:52.841Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03708224"
    },
    {
      "nct_id": "NCT01391962",
      "title": "Sunitinib or Cediranib for Alveolar Soft Part Sarcoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sarcoma, Alveolar Soft Part"
      ],
      "interventions": [
        {
          "name": "Cediranib",
          "type": "DRUG"
        },
        {
          "name": "Sunitinib",
          "type": "DRUG"
        },
        {
          "name": "Prochlorperazine",
          "type": "OTHER"
        },
        {
          "name": "Promethazine",
          "type": "OTHER"
        },
        {
          "name": "Benzodiazepine",
          "type": "OTHER"
        },
        {
          "name": "Filgrastim",
          "type": "OTHER"
        },
        {
          "name": "Sargramostim",
          "type": "OTHER"
        },
        {
          "name": "Lomotil",
          "type": "OTHER"
        },
        {
          "name": "Loperamide",
          "type": "OTHER"
        },
        {
          "name": "Vitamin B6",
          "type": "OTHER"
        },
        {
          "name": "Aquaphor",
          "type": "OTHER"
        },
        {
          "name": "Acetaminophen",
          "type": "DRUG"
        },
        {
          "name": "Levothyroxine",
          "type": "DRUG"
        },
        {
          "name": "Warfarin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "16 Years to 120 Years"
      },
      "enrollment_count": 34,
      "start_date": "2011-07-18",
      "completion_date": "2026-01-16",
      "has_results": true,
      "last_update_posted_date": "2026-02-02",
      "last_synced_at": "2026-10-27T03:06:52.841Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01391962"
    },
    {
      "nct_id": "NCT00400023",
      "title": "A Phase 1, Open-Label, Randomized, Cross-Over, Pharmacokinetic Study Evaluating the Effect of S-1 on Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Tumors"
      ],
      "interventions": [
        {
          "name": "S-1",
          "type": "DRUG"
        },
        {
          "name": "FT",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Taiho Oncology, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2006-09",
      "completion_date": "2007-05",
      "has_results": false,
      "last_update_posted_date": "2024-09-03",
      "last_synced_at": "2026-10-27T03:06:52.841Z",
      "location_count": 3,
      "location_summary": "Scottsdale, Arizona • Santa Monica, California • New Haven, Connecticut",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00400023"
    },
    {
      "nct_id": "NCT05035641",
      "title": "A Study of AND017 to Treat Anemia in Non-dialysis-Dependent Chronic Kidney Disease (NDD-CKD) Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Renal Anemia"
      ],
      "interventions": [
        {
          "name": "AND017",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kind Pharmaceuticals LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": "74 Years",
        "sex": "ALL",
        "summary": "20 Years to 74 Years"
      },
      "enrollment_count": 113,
      "start_date": "2021-10-18",
      "completion_date": "2023-07-24",
      "has_results": false,
      "last_update_posted_date": "2023-10-04",
      "last_synced_at": "2026-10-27T03:06:52.841Z",
      "location_count": 7,
      "location_summary": "Northridge, California • Winter Park, Florida • Shreveport, Louisiana + 4 more",
      "locations": [
        {
          "city": "Northridge",
          "state": "California"
        },
        {
          "city": "Winter Park",
          "state": "Florida"
        },
        {
          "city": "Shreveport",
          "state": "Louisiana"
        },
        {
          "city": "Flint",
          "state": "Michigan"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05035641"
    }
  ]
}